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Abstract
Background: Tennis elbow is a common elbow pathology typically affecting middle-aged individuals that can lead
to significant disability. Most cases resolve within 2 years of symptom onset, but a subset of patients will develop
persistent symptoms despite appropriate conservative management. There are several surgical approaches used to
treat chronic tennis elbow, with arthroscopic surgery becoming an increasingly popular approach to address this
pathology in North America. This procedure involves the arthroscopic release of the extensor carpi radialis brevis
tendon (ECRB) origin at the elbow. The potential benefit of arthroscopic treatment of this condition is improved
patient outcomes and shorter recovery time following surgery. The results of this technique have been reported
only in the context of case series, which have shown positive results. However, in order to justify its widespread
use and growing popularity, a high level of evidence study is required. The purpose of this prospective, randomized
sham-controlled trial is to determine whether arthroscopic tennis elbow release is effective at treating chronic lateral
epicondylitis.
Methods: We will conduct a prospective single center, double-blind, randomized sham-controlled parallel arm trial
evaluating the efficacy of arthroscopic tennis elbow release in adult patients with symptoms for at least 6 months.
Patients will undergo intraoperative randomization after diagnostic arthroscopy of the elbow to receive either ECRB
release (through the creation of a lateral portal) or a sham lateral portal and no ECRB release. The primary outcome
will be the Mayo Elbow Performance Score (MEPS) at 1 year follow-up. Secondary outcomes will be the abbreviated
Disability of the Shoulder and Hand (DASH) score, American Shoulder and Elbow Surgeons elbow (ASES-e) score and
grip strength at 3, 6, 12 and 24 months as well as return-to-work time, ability to return to full duty and adverse
outcomes.
Discussion: Results of this study will provide empirical high quality evidence to guide clinical decision-making in
patients with chronic tennis elbow.
Trial registration: NCT02236689 (September 8, 2014)
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Background
Lateral epicondylitis (tennis elbow) is a common occur-
rence in the general population with an incidence of 4-
7/1000/year [1–3]. More recent literature describes a
1–3 % rate over the course of a lifetime, most typically
affecting individuals between the ages of 35 and 50 [4].
Despite its name, this condition affects a wide variety
of individuals, including politicians, municipal utility
employees, cooks, meat industry employees as well as
nonlabor workers. One study looking at the financial
burden of elbow epicondylitis in Washington State
from 1987 to 1995 found that it accounted for 11.7 %
of work-related injury claims, costing $6,593 per case in
average direct workers’ compensation [5].
Although tennis elbow can present acutely, the onset
is often insidious secondary to repetitive wrist extension
and alternating forearm pro-supination. Symptoms in-
clude lateral elbow pain and forearm weakness that is
exacerbated by repetitive extension and/or rotation of
the wrist. Grip strength is also typically diminished. Its
natural history is often reported as 6–24 months, [6–8]
with more than 80 % of cases achieving complete reso-
lution at 1 year [9–11]. However, some studies report a
full recovery rate as low as 34 % by 12 months [12].
Non-operative treatment consists mainly of activity
modification, nonsteroidal antiinflammatory medications,
physical therapy, counterforce bracing and corticosteroid
injection [13]. Many authors recommend at least 6 months
of non-operative management before considering opera-
tive intervention [14, 15]. Despite these measures, some
patients will develop chronic symptoms refractory to con-
servative care.
Surgical indications for the management of lateral epi-
condylitis include persistent pain and failed adequate
conservative management. The goals of surgery are to
directly address that area of pathology through a proced-
ure that involves resection of the involved tissue, to
stimulate neovascularization and to produce a healthy
scar while doing the least possible damage to surround-
ing tissues [16]. Current surgical options can be classi-
fied into open, percutaneous and arthroscopic, with
arthroscopic tennis elbow release (ATER) having gained
popularity over the past fifteen years with improved un-
derstanding of three-dimensional elbow anatomy and
advances in arthroscopic procedures and equipment.
When performed by experienced specialists, arthro-
scopic surgery allows for the assessment and debride-
ment of concomitant intra-articular pathology such as
synovitis, radiocapitellar plicae, osteochondral defects
and intra-articular loose bodies that are often missed
and can be a frequent cause of residual pain following
extensor carpi radialis brevis (ECRB) release [17–20].
For example, in a retrospective review of 36 patients
treated arthroscopically for tennis elbow, 28 % had
significant intra-articular synovitis requiring debride-
ment [21]. The rehabilitation process and time back to
work following arthroscopic treatment is faster in com-
parison to the other surgical approaches and the out-
comes are generally reported as equal or better [17, 19,
22, 23]. A recent retrospective cohort study on 341 con-
secutive patients comparing arthroscopic to open release
demonstrated significant differences in Disability of the
Shoulder and Hand (DASH) scores and total number of
excellent outcomes between groups, favoring arthroscopy
[24].
Despite the increased popularity of ATER in recent
years, there have been no randomized-controlled trials
evaluating its efficacy. A recent systematic review con-
cluded that there is fair-quality evidence for elbow
arthroscopy in the treatment of lateral epicondylitis
(grade B recommendation) on the basis that outcomes
appear to be similar to open surgery [25]. This recom-
mendation is based on two cohort studies (Level III)
and eight case series (Level IV) all reporting good to
excellent results for arthroscopic surgery. However, a
subsequent Cochrane review concluded that due to the
small number of studies, large heterogeneity in inter-
ventions across trials, small sample sizes and poor
reporting of outcomes, there was insufficient evidence
to support or refute the effectiveness of surgery for ten-
nis elbow [26].
The arthroscopic approach to the treatment of lateral
epicondylitis has been widely adopted in North Amer-
ica. However, no comparative studies have demon-
strated its efficacy. In order to provide optimal care
to patients and to justify the increased cost and
utilization of resources required for this treatment, a
high level of evidence study is essential. This study




This study is designed as a prospective single center,
double-blind, randomized sham-controlled parallel arm
trial, stratified on the need for debridement. After diag-
nostic arthroscopy, patients will be randomly assigned to
ATER or sham (i.e. placebo) surgery and stratified by
whether they require debridement or not. The study is
designed to abide by the current international research
standards and will be reported according to the guide-
lines listed in the CONSORT statement [27]. The study
is approved by the Ottawa Health Science Network
Research Ethics Board of Ottawa, Canada and is in com-
pliance with the Tri-Council Policy Statement: Ethical
Conduct for Research Involving Humans; the Inter-
national Conference on Harmonization – Good Clinical
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Practice: Consolidated Guideline and the provisions of
the Personal Health Information Protection Act 2004.
The surgeries will be performed by a single fellowship-
trained upper extremity orthopaedic surgeon with at
least seven years of independent practice experience at a
university-affiliated academic center.
Purpose and hypothesis
The purpose of the study is to determine whether ATER
is superior to non-operative management using a sham
surgery control group for the management of chronic lat-
eral epicondylitis of the elbow at 24 months postoperative
as measured by the Mayo Elbow Performance Score
(MEPS). Data will be collected at baseline and at 3, 6, 12
and 24 months following surgery. In addition, we will aim
to determine if there is a differential effect of ATER versus
sham surgery among the subgroup of patients requiring
additional elbow debridement due to coexisting intra-
articular pathology. Furthermore, we will compare the
effect of ATER and sham surgery on the abbreviated
DASH and American Shoulder and Elbow Surgeons
Elbow (ASES-e) scores at the different timepoints, as well
as assess for any differences in grip strength, return to
work time and adverse outcomes between the two groups.
We hypothesize that at 24 months, the improvement
in MEPS is greater after ATER than sham surgery.
Furthermore, we hypothesize that the DASH, ASES-e
will also favor ATER at all postoperative timepoints. In
addition, we hypothesize that grip strength will be di-
minished in the ATER group compared to sham, but
that return to work time will favor ATER Table 1.
Participants
Patients eligible for inclusion in the study will be aged
>18 years and have had symptoms for at least 6 months
and have subsequently failed a 3-month course of con-
servative management consisting of activity modifica-
tion, anti-inflammatories, physiotherapy, corticosteroid
and platelet-rich plasma injections. Patients with an al-
ternative diagnosis that better explains their symptoms
or those who have had significant prior elbow trauma or
surgery are not eligible to be a part of the trial. Work-
place Safety and Insurance Board (WSIB) patients
(workplace injuries) are also excluded from the study.
Patients must be able to speak English. General Practi-
tioners in the Ottawa area will be sent a letter asking
them to refer patients who meet the eligibility criteria
listed above. Eligible patients will receive informed con-
sent on the two treatment arms. Enrolled participants
will undergo a functional outcome scores assessment
(MEPS, abbreviated DASH, ASES-e, grip strength) at the
second preoperative clinical visit, which will serve as a
Table 1 Data collection timeline
Variable Baselinea
Preoperative
T = 2 weeks
Postoperative
T = 6 weeks
Postoperative
T = 3 months
Postoperative
T = 6 months
Postoperative
T = 1 yearb
Postoperative





Duration of symptoms (months) X
Arm affected (L/R) X
Dominant arm (L/R) X
Height (cm) X
Weight (kg) X





MEPSc X X X X X
QuickDASH X X X X X
ASES-e X X X X X
Grip strength (grip dynamometer) X X X X X
Return to work (Y/N) X X X X
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baseline for comparison. They will then be scheduled for
surgery through the standard outpatient surgery program.
Randomization
The patients will be brought to the operating room
where they will undergo a regional block anesthetic. A
diagnostic arthroscopic evaluation will then be per-
formed through a medial portal. Following this, the sur-
geon will make a decision as to whether the elbow
requires any debridement. The decision to debride is a
clinical one and is influenced by the presence of an
intra-articular pathology, such as extensive synovitis (in-
flammation), loose bodies and radiocapitellar plicae.
Patients who are deemed to require intra-articular de-
bridement will receive it at this point. This requires the
creation of a lateral, working portal. Patients who do not
require debridement will be randomized to ATER or
sham. Similarly, patients who do require debridement
will be randomized to ATER or sham.
A randomization sequence will be computer generated
by an independent statistician. Consecutive patients will
be randomized to receive ATER or Sham surgery in a
1:1 allocation ratio, with stratification by the need for
debridement and randomly permuted block sizes from 2,
4, or 6. Central randomization will be accomplished by
the use of online registration and verification of eligibil-
ity through the Data Management Services group at the
Ottawa Hospital Research Institute Fig. 1.
ECRB release
The patient is positioned in the lateral position with the
body supported using a beanbag and the arm over a
right-angle arm support. They are padded and protected
appropriately. The patient’s bed is tilted towards the sur-
geon approximately 15° to avoid any traction on the bra-
chial plexus. The patient is then prepped and draped in
the standard sterile fashion. Anatomic landmarks are
identified and marked using a marking pen. All portal
sites are determined and marked. The elbow is injected
with 25 mL of normal saline to provide capsular disten-
tion and safer portal placement.
The anteromedial portal is established first. This is
done with a blunt trocar. The arthroscope is then
inserted into the elbow. The anterolateral portal is then
established under direct visualization. This is also com-
pleted with a blunt switch stick. A 6 mm dilator is then
placed over the switch stick.
Next, a shaver is used to remove the lateral capsule in
order to visualize the ECRB. A wedge of the capsule in
that region is removed. We are careful to avoid an antero-
lateral capsulectomy due to the proximity of the posterior
interosseus nerve in this location. We are also careful dur-
ing the procedure to avoid disrupting the ulnar lateral col-
lateral ligament by staying anterior to the equator of the
capitellum and radial head. Once the ECRB is visualized, a
biting forceps is used to release the tendon. The extensor
carpi radialis longus (ECRL) is left intact. Finally, a 1.5 ×
1.5 × 1.5 triangular section of the ECRB tendon (and
superior edge of the Extensor Digitorum Communis) ori-
gin is excised. The ECRL and LUCL are left intact. A
complete release of ECRB is performed in order to obtain
good visualization of the overlying ECRL.
After the release is completed, the elbow is examined to
demonstrate full, smooth, concentric range of motion and
to confirm that there is no evidence of catching or clicking.
The elbow is examined with varus, valgus, rotational and
axial stress to confirm that the LCL and MCL are intact.
ATER: Intervention
Patients randomized to ATER will receive arthroscopic
release of the origin of the ECRB tendon through a
standard, two-portal arthroscopic technique.
Sham surgery: Control
Patients randomized to sham surgery will not have the
ECRB muscle origin released. Instead, they may receive
a small incision only through the skin in the same pos-
ition where a second lateral portal would otherwise be
introduced, depending on whether or not they required
elbow debridement in the prior step. If debridement was
previously performed, the lateral portal will already have
been created. If no debridement was required, they will
receive a sham lateral portal, thus minimizing the risks
associated with introducing a second true portal while
also preserving the patient’s blinded status.
Postoperative protocol
Post-operative follow-up is at 2 weeks, 6 weeks, 3, 6, 12
and 24 months. Functional outcome scores will be ob-
tained from each patient at the 3, 6, 12 and 24 month time
points. Post-operative management will be identical among
the two treatment arms and consists of immediate elbow
range of motion exercises and no weight-bearing restric-
tions. However, elbow, forearm and shoulder strengthening
exercises will begin at 10 weeks postoperative. Patients (in-
dependent of concealed group allocation) will receive func-
tional counseling by a licenced physiotherapist at the first
postoperative visit and will be provided with a standardized
exercise protocol to guide outpatient physiotherapy.
Primary outcome
MEPS
All functional assessment forms will be administered
electronically to patients by means of a touch-screen de-
vice at each follow-up appointment. Our primary out-
come measure is elbow pain and function as measured
by the MEPS at 24 months post-operative. The MEPS is
a commonly used performance index for evaluation of
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clinical outcomes for a variety of elbow disorders that
can be completely patient-administered [28]. It consists
of four parts: pain, stability, ulnohumeral motion and
the ability to perform five functional tasks. The highest
possible score is 100, with scores 90 and above indicat-
ing excellent function [29].
Fig. 1 Study flowchart. Legend: two parallel randomization arms; ATER (blue) and sham procedure (green)
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Secondary outcomes
DASH
The abbreviated (quick) DASH score is a self-reported
questionnaire consisting of 11 items designed to meas-
ure symptoms and function in patients with upper
extremity-specific pathologies. It is a shortened version
of the DASH score, which normally consists of 30 items,
and has been shown to retain its psychometric proper-
ties in a more user-friendly structure. At least 10 of the
11 items must be completed in order for the score to be
valid. Each item is scored 1-5, with 1 indicating no diffi-
culty and 5 indicating inability to perform the function
questioned. The values are then summed up, averaged
and converted to a score out of 100 by subtracting 1 and
multiplying by 25. The higher the score, the greater the
disability [30].
ASES-e
The ASES-e score is both patient and physician-
administered. The patient-reported self-evaluation con-
sists of pain, function and satisfaction components. The
pain component utilizes the visual analogue scale (0 to
10, with 10 indicating the worst pain ever), while the
function component pertains to the patient’s ability to
perform specific upper extremity-related tasks (0 to 4,
with 4 indicating no difficulty). Satisfaction is graded 0
to 10. The physician assessment consists of motion,
strength (both in flexion, extension, pro-supination), sta-
bility (varus, valgus, posterolateral rotatory) and physical
findings (tenderness, scars, etc). Stability is graded 0 to
3, with 3 grading gross instability, while strength is
graded 0 to 5, with 5 indicating normal strength. Phys-
ical findings are reported as being present or not.
The MEPS, DASH and ASES-e scores are all validated,
upper extremity-specific questionnaires [29]. We will
also be testing grip strength using a standard grip dyna-
mometer and compare return to work time and adverse
outcomes between the two groups.
Blinding
Patients will be blinded to treatment group through
the use of a sham incision. Due to the nature of a sur-
gical trial, the surgeon cannot be blinded to the inter-
vention. However, a trained independent assessor,
blinded to treatment status will conduct the follow-up
examinations in a standardized fashion. This will
minimize the potential for biases introduced by the
examiner when performing the physical assessment
and recording data. The assessor will not have access
to the patient chart prior to the examination. To help
reduce the potential for observer bias, the physical
examination and the administration of study question-
naires are standardized.
Control of contamination and co-intervention
There will be a possibility of cross-over after one year
postoperative. This means that to remain a study par-
ticipant, the patient may not learn which of the two
groups they were randomized to until one year postop-
erative. However, should the patient be unsatisfied with
their outcome prior to that mark, they may elect to
withdraw themselves from the study and learn which
treatment they received and pursue further treatment if
appropriate.
Ensuring complete follow-up
The following measures will help to ensure completion
of follow-up: a) study patients will supply their own ad-
dress, telephone and email information as well as the
name, relationship, address, telephone and email infor-
mation of someone who does not reside with the patient,
but is likely to have contact with them should they move
or change telephone information, b) patients will receive
a copy of the consent form which will outline the pur-
pose of the study, the importance of their individual par-
ticipation and attendance for follow-up assessments and




The primary analysis involves a comparison of the MEPS
outcome measure between the two surgical treatment
groups on an intention-to-treat basis at 24 months post-
surgery as compared to baseline values. A two-sample
independent ANCOVA will be used to assess whether
there is a statistically significant difference between
groups for the MEPS scores, accounting for the debride-
ment stratification variable and baseline MEPS. Linear
regression will be used to estimate treatment size effect,
accounting for the stratification variable and baseline
MEPS, as well as any possible imbalanced covariates.
Primary analyses will be repeated for the debridement
and no-debridement patient subgroups. Missing follow-
up data will be addressed with multiple imputation
techniques.
Secondary analysis
A generalized estimated equations (GEE) analysis will be
conducted to determine whether there is an effect of
treatment arm over time (repeated measures) on the
MEPS outcome, considering measures taken preopera-
tively, and at 3, 6, 12 and 24 month follow-ups. Other
secondary analyses involves a comparison of the second-
ary outcome measures between the two surgical treat-
ment groups. Differences in the mean abbreviated
DASH and ASES-e scores, as well as grip strength, will
be tested with ANOVAs and effect sizes estimated with
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linear regression. Median time back to work in each
group will be derived with Kaplan-Meier survival curves,
and a statistical comparison between groups will be
tested using a log rank test.
Sample size calculation
The primary outcome is the modified Mayo Elbow Per-
formance score. A minimum clinically importance differ-
ence of 15 points has been derived for patients with
rheumatoid arthritis [31]. In a study of patients with
elbow dysfunction, standard deviations ranged from 17
to 19 points [28]. In order to attain a study power of
80 % to detect a minimally clinically important differ-
ence of 15 points on the MEPS primary outcome meas-
ure at one year follow-up using ANOVA to compare
ATER versus sham, and assuming a standard deviation
of 19 points as well as an alpha level of 0.05, a total sam-
ple size of 52 patients will be required (group sizes of
26) [31, 32]. However, adjusting for the remote possibil-
ity of 5 % of patients requiring un-blinding in the case of
sham surgery (drop out), and a possible 15 % loss to
follow-up yields a total sample size of 68 (34 in each
group).
Assuming a recruitment and consent rate of 70 %, we
would need to approach 97 patients to achieve our re-
quired sample size. Hospital records indicate that our
clinic sees approximately 10 eligible patients per month,
meaning we can feasibly achieve our required sample
size within 10 months of enrollment.
Patients who are excluded from the trial intra-
operatively and patients whose symptoms resolve prior
to intra-operative randomization will only be followed
clinically and not as part of this study.
Discussion
We would like to stress the importance of considering
risk when attempting to answer a clinical question. In
any surgical study, participants are subjected to the pos-
sibility of suffering an adverse event and our proposed
trial is no different. Thus, it is imperative from an ethical
point of view to answer the following questions: 1) is the
question worth asking, 2) is there an alternative, less
risky approach that adequately answers the question,
and 3) are the risks justified by the expected benefits of
answering the question? The first point was previously
addressed in our discussion about the rate of affliction
of tennis elbow and the lack of evidence to support the
efficacy of a commonly performed orthopaedic proced-
ure aimed at treating it. We will thus focus our attention
to points 2 and 3.
We strongly considered the alternative of having a
control arm consisting of conservative management in-
stead of diagnostic arthroscopy, as this would have been
a less invasive option. However, a trial of this design
would fail to further advance our understanding of the
efficacy of ATER for the following reasons. Firstly, out-
come raters could foreseeably become un-blinded if the
patient communicates that they had surgery, as was pre-
viously shown to have occurred in a study of surgery
versus splinting for carpal tunnel syndrome [33]. Second,
there is a significant potential for recall bias given the
outcome measures used. While the MEPS, abbreviated
DASH and ASES-e questionnaires are validated scales
for data acquisition, thereby lowering the risk of recall
bias, they are nevertheless based on patient-reported
data and are therefore at risk of bias [33]. Furthermore,
patients included in the study would have already
attempted and failed appropriate conservative manage-
ment. Therefore subjecting them to the same failed ther-
apy for a period of time exceeding the expected natural
history of the disease would be of no added benefit to
them.
Although patients randomized to sham surgery are
not expected to directly benefit from their procedure,
the diagnostic arthroscopy they would have received
prior to intra-operative randomization is therapeutic in
the sense that it allows for assessment and treatment
of potential concomitant pathology, which may be
present. A trial design of ATER versus non-operative
management would prevent us from performing this
assessment.
When looking at the complications of arthroscopic
elbow surgery, it is important to consider the different
pathologies separately as each one carries a different
risk quotient. Elbow arthroscopy performed for the
treatment of osteoarthritis, inflammatory arthritis and
loose body removal has about a 0.8 % rate of joint in-
fection [34]. Furthermore, a recent retrospective review
of 1004 elbow arthroscopy procedures identified a tran-
sient neurologic deficit in 4 patients (2 ulnar, 1 radial
nerve palsies), all of whom had complete resolution of
symptoms by 6 weeks postoperative, and one perman-
ent ulnar nerve palsy secondary to direct injury to the
nerve (discovered on subsequent exploratory surgery)
[35]. Conversely, arthroscopic surgery specifically for
tennis elbow has an extremely low risk of complica-
tions. In a case-control series of 225 elbows treated
arthroscopically for tennis elbow, there were no major
complications such as deep infection, permanent nerve
injuries or elbow stiffness [24]. Thus, the primary bur-
den of undergoing this procedure is pain at the surgical
site. However, pain from arthroscopic surgery is gener-
ally low-grade and well-tolerated by patients. We
believe that the risks of our proposed study are out-
weighed by the expected benefit of being able to defin-
itely answer whether arthroscopic tennis elbow release
efficaciously treats the common pathology of chronic
lateral epicondylitis.
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